Stock Traders Purchase High Volume of Teva Pharmaceutical Industries Put Options (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) was the recipient of some unusual options trading on Monday. Investors acquired 86,445 put options on the stock. This represents an increase of approximately 136% compared to the average daily volume of 36,670 put options.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on TEVA. StockNews.com downgraded Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a research note on Monday. Bank of America cut their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. UBS Group cut their price target on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Barclays cut their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a research report on Thursday, January 30th. Finally, Piper Sandler increased their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $23.43.

Teva Pharmaceutical Industries Stock Performance

TEVA traded up $0.18 on Friday, reaching $13.61. The company had a trading volume of 8,836,138 shares, compared to its average volume of 9,903,611. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries has a 1 year low of $12.47 and a 1 year high of $22.80. The stock has a market capitalization of $15.43 billion, a PE ratio of -9.38, a P/E/G ratio of 1.44 and a beta of 0.72. The stock has a 50-day moving average price of $15.45 and a 200-day moving average price of $17.67.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, research analysts forecast that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Oarsman Capital Inc. purchased a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $29,000. Marshall & Sterling Wealth Advisors Inc. purchased a new position in shares of Teva Pharmaceutical Industries in the 4th quarter valued at approximately $44,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $50,000. Compagnie Lombard Odier SCmA acquired a new position in shares of Teva Pharmaceutical Industries in the first quarter valued at approximately $54,000. Finally, Ameliora Wealth Management Ltd. purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $66,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.